{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2010-P-0614\" sorted by posted_date descending", "rows": [["FDA-2010-P-0614-0079", "FDA", "FDA-2010-P-0614", "Attachment 1 - \"Supporting Research and Development to Promote Economic Growth: The Federal Government's Role\" - [Mutual Pharmaceutical Company, Inc., (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-21T04:00:00Z", 2011, 6, null, null, "2011-06-21T15:21:02Z", null, 0, 0, "0900006480d0391b"], ["FDA-2010-P-0614-0080", "FDA", "FDA-2010-P-0614", "Attachment 2 - \"Frequently Asked Questions About Drug Shortage\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-21T04:00:00Z", 2011, 6, null, null, "2011-06-21T15:21:02Z", null, 0, 0, "0900006480d0391c"], ["FDA-2010-P-0614-0081", "FDA", "FDA-2010-P-0614", "Attachment 3 - \"Questions and Answers: Delayed-Release Pancreatic Enzyme Product Receives FDA Approval\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-21T04:00:00Z", 2011, 6, null, null, "2011-06-21T15:21:02Z", null, 0, 0, "0900006480d0391d"], ["FDA-2010-P-0614-0077", "FDA", "FDA-2010-P-0614", "Attachment 6 - \"StatCrunch re FMF: Patients' Responses to Colchine, February 22, 2010\"", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-17T04:00:00Z", 2011, 6, null, null, "2011-06-17T22:54:24Z", null, 0, 0, "0900006480c7a19f"], ["FDA-2010-P-0614-0075", "FDA", "FDA-2010-P-0614", "Attachment 4 - \"e-Correspondence, re Westward, etc., December 15, 2009\"", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-17T04:00:00Z", 2011, 6, null, null, "2011-06-17T22:47:45Z", null, 0, 0, "0900006480c79c28"], ["FDA-2010-P-0614-0076", "FDA", "FDA-2010-P-0614", "Attachment 5 - \"e-Correspondence re Colchicine Assistance Program, February 22, 2010\"", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-17T04:00:00Z", 2011, 6, null, null, "2011-06-17T22:47:45Z", null, 0, 0, "0900006480c79c29"], ["FDA-2010-P-0614-0074", "FDA", "FDA-2010-P-0614", "Attachment 2 - \"Declaration and Curriculum Vitae, Dr. Thomas J. Maronick, DBA, JD\"", "Supporting & Related Material", "Reply Comment (RC)", "2011-06-17T04:00:00Z", 2011, 6, null, null, "2011-06-17T22:47:44Z", null, 0, 0, "0900006480c79c26"], ["FDA-2010-P-0614-0072", "FDA", "FDA-2010-P-0614", "FDA/CDER to Sidley Austin LLP - Petition Partial Approval and Denial", "Other", "PPAD-Petition Partial Approval and Denial", "2011-05-25T04:00:00Z", 2011, 5, "2011-05-25T04:00:00Z", null, "2013-07-27T23:54:06Z", null, 0, 0, "0900006480e3245f"], ["FDA-2010-P-0614-0070", "FDA", "FDA-2010-P-0614", "Appendix 2 -  \"American College of Rheumatory to FDA re huge price increases in the Colchicine Market, December 18, 2009\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement] re FDA-2010-P-0614-0069", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-17T04:00:00Z", 2011, 5, null, null, "2011-05-17T21:25:51Z", null, 0, 0, "0900006480c79ac3"], ["FDA-2010-P-0614-0071", "FDA", "FDA-2010-P-0614", "Appendix 3 -  \"Summary of January 21 Teleconference with FDA Regarding Colchicine\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement] re FDA-2010-P-0614-0069", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-17T04:00:00Z", 2011, 5, null, null, "2011-05-17T21:26:28Z", null, 0, 0, "0900006480c79ac4"], ["FDA-2010-P-0614-0069", "FDA", "FDA-2010-P-0614", "West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement", "Other", "SUP-Supplement", "2011-05-17T04:00:00Z", 2011, 5, "2011-05-17T04:00:00Z", null, "2013-07-27T23:52:55Z", null, 0, 0, "0900006480c79ac1"], ["FDA-2010-P-0614-0067", "FDA", "FDA-2010-P-0614", "Appendix 6 - \"Qualaquin, URL Pharma\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:29:16Z", null, 0, 0, "0900006480c40c2f"], ["FDA-2010-P-0614-0062", "FDA", "FDA-2010-P-0614", "Appendix 1 - \"Motion to Dismiss, King Pharmaceuticals, Inc., and Jones Pharma, Inc., v. FDA, et al., US District Court for the District of Columbia, No.1:04cv01058(RBW)\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:04:49Z", null, 0, 0, "0900006480c40c2a"], ["FDA-2010-P-0614-0063", "FDA", "FDA-2010-P-0614", "Appendix 2 - \"Colchicine, E-mail Message, February 23, 2011\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:14:55Z", null, 0, 0, "0900006480c40c2b"], ["FDA-2010-P-0614-0065", "FDA", "FDA-2010-P-0614", "Appendix 4 - \"Patent Information Submitted Upon and After Approval of an NDA or Supplement, Form FDA 3542\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:18:16Z", null, 0, 0, "0900006480c40c2d"], ["FDA-2010-P-0614-0066", "FDA", "FDA-2010-P-0614", "Appendix 5 - \"Complaint for Declaratory Judgement, Mutual Pharmaceutical Company v. West-Ward Pharmaceutical Corporation, April 21, 2011\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:24:52Z", null, 0, 0, "0900006480c40c2e"], ["FDA-2010-P-0614-0061", "FDA", "FDA-2010-P-0614", "West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement", "Other", "SUP-Supplement", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2013-08-11T04:45:41Z", null, 0, 0, "0900006480c40772"], ["FDA-2010-P-0614-0064", "FDA", "FDA-2010-P-0614", "Appendix 3 - \"U.S.  Patent Nos. 7,619,004 and 7,820,681\" - [West-Ward Pharmaceutical Corporation (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-05-10T04:00:00Z", 2011, 5, null, null, "2011-05-10T22:14:19Z", null, 0, 0, "0900006480c40c2c"], ["FDA-2010-P-0614-0058", "FDA", "FDA-2010-P-0614", "Tab 20 - \"FDA/CDER Chemistry Review(s) for NDA 21-342, Levo-T\u00ae (levothyroxine sodium tablets, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:42Z", null, 0, 0, "0900006480c2b452"], ["FDA-2010-P-0614-0048", "FDA", "FDA-2010-P-0614", "Tab 10 - \"FDA News Release: FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:23Z", null, 0, 0, "0900006480c263c4"], ["FDA-2010-P-0614-0054", "FDA", "FDA-2010-P-0614", "Tab 16 - \"FDA/CDER Response to Pennie & Edmonds, LLP, Oct. 1, 2003\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:35Z", null, 0, 0, "0900006480c27c69"], ["FDA-2010-P-0614-0042", "FDA", "FDA-2010-P-0614", "Tab 1 - \"Transcript of FDA's Marketed Unapproved Drug Workshop, Pages 278-279, (Jan. 9, 2007)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:11Z", null, 0, 0, "0900006480c2617a"], ["FDA-2010-P-0614-0043", "FDA", "FDA-2010-P-0614", "Tab 3 - \"FDA/CDER Summary Review for Regulatory Action for NDA 22-353, Colcrys\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:13Z", null, 0, 0, "0900006480c2617c"], ["FDA-2010-P-0614-0049", "FDA", "FDA-2010-P-0614", "Tab 11 - \"Package Insert for Probenecid and Colchicine Tablets (Watson Laboratories, Inc.)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:25Z", null, 0, 0, "0900006480c26b62"], ["FDA-2010-P-0614-0044", "FDA", "FDA-2010-P-0614", "Tab 5 - \"Approved Product Labeling for Colchicine Tablet (Rebel Distributors Corp.)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:15Z", null, 0, 0, "0900006480c2617e"], ["FDA-2010-P-0614-0045", "FDA", "FDA-2010-P-0614", "Tab 6 - \"Approved Product Labeling for Colchicine Tablet (RemedyRepack, Inc.)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:17Z", null, 0, 0, "0900006480c2617f"], ["FDA-2010-P-0614-0051", "FDA", "FDA-2010-P-0614", "Tab 13 - \"FDA/CDER Administrative and Correspondence Documents Related to NDA 22-353, Colcrys\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:29Z", null, 0, 0, "0900006480c27c66"], ["FDA-2010-P-0614-0055", "FDA", "FDA-2010-P-0614", "Tab 17 - \"FDA/CDER Chemistry Review(s) for NDA 21-116, Thyro-Tabs\u00ae (levothyroxine sodium tablets, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:36Z", null, 0, 0, "0900006480c27c6a"], ["FDA-2010-P-0614-0046", "FDA", "FDA-2010-P-0614", "Tab 7 - \"Approved Prescribing Information for Colchicine (Colchicine Tablet) (West-ward Pharmaceutical Corp.)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:19Z", null, 0, 0, "0900006480c263bf"], ["FDA-2010-P-0614-0050", "FDA", "FDA-2010-P-0614", "Tab 12 - \"FDA/CDER Cross Discipline Team Leader Review of NDA 22-353, Colcrys (Colchicine)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:27Z", null, 0, 0, "0900006480c27c63"], ["FDA-2010-P-0614-0060", "FDA", "FDA-2010-P-0614", "Tab 23 - \"FDA/CDER Cross Discipline Team Leader Review for NDA 22-351, Colcrys (colchicine)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:46Z", null, 0, 0, "0900006480c2b455"], ["FDA-2010-P-0614-0047", "FDA", "FDA-2010-P-0614", "Tab 9 - \"Disclosure of FOIA Request Log for Control No. 2009-6835, August 26, 2009 \" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:21Z", null, 0, 0, "0900006480c263c3"], ["FDA-2010-P-0614-0052", "FDA", "FDA-2010-P-0614", "Tab 14 - \"FDA/CDER Response to Osmotica Pharmaceutical Corp., Nov. 25, 2008\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:31Z", null, 0, 0, "0900006480c27c67"], ["FDA-2010-P-0614-0057", "FDA", "FDA-2010-P-0614", "Tab 19 - \"FDA/CDER Chemistry Review(s) for NDA 21-402, Synthroid\u00ae (levothyroxine sodium tablets, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:40Z", null, 0, 0, "0900006480c27c6c"], ["FDA-2010-P-0614-0059", "FDA", "FDA-2010-P-0614", "Tab 22 - \"Chemistry Review(s) for NDA 21-137, Levolet\u00ae (levothyroxine sodium tablets, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:44Z", null, 0, 0, "0900006480c2b454"], ["FDA-2010-P-0614-0056", "FDA", "FDA-2010-P-0614", "Tab 18 - \"FDA/CDER Chemistry Review(s) for NDA 21-292, Novothyrox (levothyroxine sodium tablet, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:38Z", null, 0, 0, "0900006480c27c6b"], ["FDA-2010-P-0614-0053", "FDA", "FDA-2010-P-0614", "Tab 15 - \"FDA/CDER Response to Osmotica Pharmaceutical Corp., Jan. 21, 2010\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:33Z", null, 0, 0, "0900006480c27c68"], ["FDA-2010-P-0614-0033", "FDA", "FDA-2010-P-0614", "Appendix 11 - \"November 20, 2004 Letter From Galson (FDA) to Beers and Cavanaugh Regarding Docket No. 2004P-0386\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:42:11Z", null, 0, 0, "0900006480c2da29"], ["FDA-2010-P-0614-0030", "FDA", "FDA-2010-P-0614", "Appendix 8 - \"Draft Guidance for Industry: Application Covered by Section 505(b)(2), (October 1999)\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:34:11Z", null, 0, 0, "0900006480c2da11"], ["FDA-2010-P-0614-0041", "FDA", "FDA-2010-P-0614", "Appendix 21 - \"Rockoff, An Old Gout Drug Gets New Life an a New Price, Riling Patients, Drug, July 7, 2010\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T23:32:51Z", null, 0, 0, "0900006480c2e382"], ["FDA-2010-P-0614-0037", "FDA", "FDA-2010-P-0614", "Appendix 17 - \"Teva Pharms., USA, Inc. v. FDA, 182 F. 3d 1003, (D.C. Cir.1999)-  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T23:04:16Z", null, 0, 0, "0900006480c2e19a"], ["FDA-2010-P-0614-0038", "FDA", "FDA-2010-P-0614", "Appendix 18 - \"Civil Minutes From Mutual Pharm. Co, Inc. v. West-Ward Pharm. Corp. Et al, Civ. Action 09-05700 (C.D. Cal. 2010)\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T23:06:40Z", null, 0, 0, "0900006480c2e19b"], ["FDA-2010-P-0614-0039", "FDA", "FDA-2010-P-0614", "Appendix 20 - \"Miller, The Price of Gout Drug Colchicine, Goes Up, April 20, 2010\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T23:11:25Z", null, 0, 0, "0900006480c2e381"], ["FDA-2010-P-0614-0036", "FDA", "FDA-2010-P-0614", "Appendix 14 - \"Redacted  Letter From Chowdhury (FDA) to West-Ward Pharmaceutical Corporation\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:55:46Z", null, 0, 0, "0900006480c2e197"], ["FDA-2010-P-0614-0032", "FDA", "FDA-2010-P-0614", "Appendix 10 - \"FDA, Clinical Review for NDA 22-353\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:41:47Z", null, 0, 0, "0900006480c2da28"], ["FDA-2010-P-0614-0031", "FDA", "FDA-2010-P-0614", "Appendix 9 - \"FDA, Summary Review for Regulatory Action for NDA 22-353\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:36:17Z", null, 0, 0, "0900006480c2da12"], ["FDA-2010-P-0614-0034", "FDA", "FDA-2010-P-0614", "Appendix 12 - \"August 1, 2008 Letter from Mutual Pharmaceutical Company, Inc. re: Citizen Petition Submission (Docket No. FDA-2008-P-0442)\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:45:19Z", null, 0, 0, "0900006480c2e0ac"], ["FDA-2010-P-0614-0028", "FDA", "FDA-2010-P-0614", "West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement", "Other", "SUP-Supplement", "2011-04-22T04:00:00Z", 2011, 4, "2011-04-22T04:00:00Z", null, "2013-07-27T23:50:28Z", null, 0, 0, "0900006480c2d939"], ["FDA-2010-P-0614-0035", "FDA", "FDA-2010-P-0614", "Appendix 13 - \"December 18, 2009 Letter from Stanley Cohen, MD to Janet Woodcock re: Removal of Unapproved Colchicine\" -  [West-Ward Pharmaceutical Group (Arnall Golden Gregory LLP) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-04-22T04:00:00Z", 2011, 4, null, null, "2011-04-22T22:53:40Z", null, 0, 0, "0900006480c2e196"], ["FDA-2010-P-0614-0026", "FDA", "FDA-2010-P-0614", "Janine Jagger, M.P.H., Ph.D., to FDA - Letter", "Other", "LET-Letter", "2011-04-11T04:00:00Z", 2011, 4, "2011-04-11T04:00:00Z", null, "2013-08-11T01:40:49Z", null, 0, 0, "0900006480c18eec"], ["FDA-2010-P-0614-0023", "FDA", "FDA-2010-P-0614", "Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) to FDA/CDER - Letter", "Other", "LET-Letter", "2011-03-18T04:00:00Z", 2011, 3, "2011-03-18T04:00:00Z", null, "2013-07-27T23:46:50Z", null, 0, 0, "0900006480c025de"], ["FDA-2010-P-0614-0019", "FDA", "FDA-2010-P-0614", "Tab 16 - \"FDA Administrative and Correspondence Documents for NDA 22-351:  Minutes from Type B Pre-IND Meeting Between FDA and Mutual Pharmaceutical Company, Inc.,\" July 31, 2006 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:15Z", null, 0, 0, "0900006480bc1b4c"], ["FDA-2010-P-0614-0011", "FDA", "FDA-2010-P-0614", "Tab 6 - FDA Information for Healthcare Professionals, \"New Safety Information for Colchicine (Marketed as Colcrys),\" July 30, 2009 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:02Z", null, 0, 0, "0900006480bc1ae1"], ["FDA-2010-P-0614-0014", "FDA", "FDA-2010-P-0614", "Tab 9 - \"Letter from FDA's Center for Drug Evaluation and Research to Osmotica Pharmaceutical Corp. regarding Docket No. FDA-2008-P-0329,\" dated November 25, 2008 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:07Z", null, 0, 0, "0900006480bc1ae4"], ["FDA-2010-P-0614-0008", "FDA", "FDA-2010-P-0614", "Tab 1 - FDA Consumer Information, \"New Label Information Affecting All Approved Protease Inhibitors for Treatment of HIV\" - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:30:41Z", null, 0, 0, "0900006480bc1745"], ["FDA-2010-P-0614-0012", "FDA", "FDA-2010-P-0614", "Tab 7 - \"Letter from FDA's Center for Drug Evaluation and Research to Arnold & Porter, LLP and Patterson, Belknap, Webb & Tyler, LLP regarding Docket No. 2004P-0386,\" dated November 30, 2004 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:03Z", null, 0, 0, "0900006480bc1ae2"], ["FDA-2010-P-0614-0015", "FDA", "FDA-2010-P-0614", "Tab 12 - \"Allopurinol Package Insert\" - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:09Z", null, 0, 0, "0900006480bc1ae9"], ["FDA-2010-P-0614-0017", "FDA", "FDA-2010-P-0614", "Tab 14 - \"FDA Clinical Review for NADA 22-353\" dated August 5, 2009 (Relevant Pages) - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:12Z", null, 0, 0, "0900006480bc1b48"], ["FDA-2010-P-0614-0018", "FDA", "FDA-2010-P-0614", "Tab 15 - \"FDA Clinical Pharmacology and Biopharmaceutics Review(s) for NDA 22-352,\" dated November 26, 2008 (Relevant Pages) - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:14Z", null, 0, 0, "0900006480bc1b4b"], ["FDA-2010-P-0614-0010", "FDA", "FDA-2010-P-0614", "Tab 3 - \"Declaration of E. Marro in Support of Defendant West-Ward Pharmaceutical Corp.'s Response in Opposition to Plaintiff's Motion for Preliminary Injunction\" - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:00Z", null, 0, 0, "0900006480bc1908"], ["FDA-2010-P-0614-0016", "FDA", "FDA-2010-P-0614", "Tab 13 - \"Letter from FDA's Center for Drug Evaluation and Research to Covington & Burling (Wyeth Pharmaceuticals) regarding Docket No. 2003P-0518\" dated September 20, 2004 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:10Z", null, 0, 0, "0900006480bc1b45"], ["FDA-2010-P-0614-0009", "FDA", "FDA-2010-P-0614", "Tab 2 - \"Open Letter from FDA's Center for Drug Evaluation and Research regarding Unapproved Colchicine\" - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:33:58Z", null, 0, 0, "0900006480bc1906"], ["FDA-2010-P-0614-0013", "FDA", "FDA-2010-P-0614", "Tab 8 - \"Letter from FDA's Center for Drug Evaluation and Research to Sanzo, et. al., regarding Docket Nos. 2001P-0323, 2002P-0447, and 2003P-0408,\" dated October 14, 2004 - [Sidley Austin, LLP - (Mutual Pharmaceutical Company, Inc.) - Supplement]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2011-01-20T05:00:00Z", 2011, 1, null, null, "2011-01-20T17:34:05Z", null, 0, 0, "0900006480bc1ae3"], ["FDA-2010-P-0614-0007", "FDA", "FDA-2010-P-0614", "Sidley Austin, LLP [Mutual Pharmaceutical Company, Inc.] - Supplement", "Other", "SUP-Supplement", "2011-01-19T05:00:00Z", 2011, 1, "2011-01-19T05:00:00Z", null, "2013-08-11T03:12:27Z", null, 0, 0, "0900006480bc1744"], ["FDA-2010-P-0614-0004", "FDA", "FDA-2010-P-0614", "Attachment 2  Highlights of Prescribing Information  [Mutual Pharmaceutical Company, Inc. Citizen petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2010-12-08T05:00:00Z", 2010, 12, null, null, "2010-12-08T21:18:40Z", null, 0, 0, "0900006480baa7f3"], ["FDA-2010-P-0614-0006", "FDA", "FDA-2010-P-0614", "Attachment 4  Letter From Center for Drugs [Mutual Pharmaceutical Company, Inc.  Citizen petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2010-12-08T05:00:00Z", 2010, 12, null, null, "2010-12-08T21:18:13Z", null, 0, 0, "0900006480baa852"], ["FDA-2010-P-0614-0001", "FDA", "FDA-2010-P-0614", "Acknowledgement Letter to Sidley Austin LLP [Mutual Pharmaceutical Company, Inc.]", "Other", "ACK-Acknowledgement Letter", "2010-12-08T05:00:00Z", 2010, 12, "2010-12-08T05:00:00Z", null, "2010-12-08T21:01:59Z", null, 0, 0, "0900006480baa855"], ["FDA-2010-P-0614-0003", "FDA", "FDA-2010-P-0614", "Attachment 1 Colchicine Tablets USP [Mutual Pharmaceutical Company, Inc. Citizen petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2010-12-08T05:00:00Z", 2010, 12, null, null, "2024-11-12T05:00:59Z", null, 0, 0, "0900006480baa773"], ["FDA-2010-P-0614-0005", "FDA", "FDA-2010-P-0614", "Attachment 3  Marion Merrell Dow, Inc. et al Plaintiffs, V. Hoechst-Roussel Pharmaceuticals, Inc. Defendant  [Mutual Pharmaceutical Company, Inc. Citizen petition]", "Supporting & Related Material", "CP-Citizen Petition (Supporting & Related Materials)", "2010-12-08T05:00:00Z", 2010, 12, null, null, "2010-12-08T21:16:39Z", null, 0, 0, "0900006480baa774"]], "truncated": false, "filtered_table_rows_count": 69, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2010-P-0614"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2010-P-0614", "results": [{"value": "FDA", "label": "FDA", "count": 69, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2010-P-0614", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 61, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 8, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2010-P-0614", "results": [{"value": 2011, "label": 2011, "count": 64, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&posted_year=2011", "selected": false}, {"value": 2010, "label": 2010, "count": 5, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&posted_year=2010", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2010-P-0614&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 8.394340053200722, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}